Surface Oncology Inc

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.

Award recognizes the best employers in Massachusetts Award recognizes the best employers in Massachusetts

Surface Oncology Named a 2021 Top Place to Work by the Boston Globe

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021, to be held virtually from December 8 to 11, 2021.

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG

Adaptive Biotechnologies

Exact Sciences

The internet's favorite stock picker has been very busy.

Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that two scientific posters sharing updated preclinical data from Surface Oncology's two lead clinical-stage antibody therapies, SRF617 (targeting CD39) and SRF388 (targeting IL-27), will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021.

Preclinical Data Supporting Therapeutic Potential of Surface Oncology's Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the upcoming Cowen Fifth Annual IO Next Summit on Monday, November 15, 2021 at 12:45 p.m. ET.

Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit

Company to initiate randomized Phase 2 clinical study evaluating SRF388 in combination with Roche's atezolizumab and bevacizumab, in patients with treatment-naïve HCC Company to initiate randomized Phase 2 clinical study evaluating SRF388 in combination with Roche's atezolizumab and bevacizumab, in patients with treatment-naïve HCC

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that scientific posters sharing preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021.

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Study initiation underway with first patient dosed by early 2022 Study initiation underway with first patient dosed by early 2022

Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche

AstraZeneca

The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.

Why AstraZeneca and Surface Oncology Rose Today

The stock price of Surface Oncology Inc (NASDAQ: SURF) increased today. This is why it happened.

SURF Stock: Why It Increased Today

SRF388, a First-in-Class Anti-IL-27 Antibody, Demonstrates Monotherapy Activity in Ongoing Phase 1 Study; Enrollment Continues for Phase 2 Monotherapy Expansion and Combination Cohorts

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

Codexis

CM Life Sciences II Inc - Unit

Iridium Communications

Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.

ARK Investment Leans Into Biotech and Telecom Holdings

Brings 25 years of strategic leadership experience across healthcare Brings 25 years of strategic leadership experience across healthcare

Surface Oncology Appoints Denice Torres to Board of Directors

Surface Oncology (NASDAQ: SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.

Surface Oncology's SRF388 Shows Promising Anticancer Activity in Pretreated Patients

Roche Holding AG

Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab has been shown to improve overall survival significantly and is the new standard of care for unresectable or metastatic HCC.

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches

SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, Surface's investigational anti-IL-27 antibody, in combination with Roche's atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC).

Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma

It's the right time to be decisive, if you can tolerate uncertainty.

This Is Why Surface Oncology Is a Great Stock to Buy Right Now

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

Implied Volatility Surging for Surface Oncology (SURF) Stock Options

Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.

Could Surface Oncology Be a Millionaire-Maker Stock?

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2021, as well as anticipated corporate milestones for the second quarter 2021.

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021

SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting

Surface Oncology to Present Clinical Updates for SRF388 and SRF617

Henry Rath announced as chief business officer, Alison O'Neill as chief medical officer and Jessica Fees as chief financial officer Henry Rath announced as chief business officer, Alison O'Neill as chief medical officer and Jessica Fees as chief financial officer

Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions

BioDelivery Sciences

Co-Diagnostics

Kamada

Viemed Healthcare

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

News for Surface Oncology Inc Stock (SURF)